Skip to main content
. 2010 Nov 30;103(12):1852–1857. doi: 10.1038/sj.bjc.6605970

Figure 1.

Figure 1

Overview of the analysis performed to develop and validate a novel prognostic gene expression signature for stage 2 and 3 colon cancer. After selection of genes significantly associated with outcome in log-intensity scale, data were converted to percent-rank values and used to re-train the predictive metagene algorithm.